Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Abobotulinumtoxina Efficacy And Safety In Children With Upper Limb Spasticity Previously Treated With Botulinum Toxin, Edward Dabrowski, Mauricio R. Delgado, Joyce Oleszek, Nigar Dursun, Jorge Carranza Del-Rio, Marcin Bonikowski, Benjamin Regnault, Simon Page, Ann Tilton
Abobotulinumtoxina Efficacy And Safety In Children With Upper Limb Spasticity Previously Treated With Botulinum Toxin, Edward Dabrowski, Mauricio R. Delgado, Joyce Oleszek, Nigar Dursun, Jorge Carranza Del-Rio, Marcin Bonikowski, Benjamin Regnault, Simon Page, Ann Tilton
Conference Presentation Abstracts
Introduction: Primary endpoint analysis of this phase 3 study confirmed abobotulinumtoxinA (aboBoNT-A 8 U/kg and 16 U/kg) significantly reduced hypertonia versus the 2 U/kg low-dose control and was generally well tolerated (Delgado, et al, 2021). However, the impact of previous botulinum neurotoxin (BoNT) injections on treatment outcomes remains largely unexplored.
Methods: We present subgroup analyses of a phase 3 study conducted in children (aged 2-17) with cerebral palsy (Gross Motor Function Classification System [GMFCS] Levels I-IV) and spasticity in ≥1 upper limb. In the first treatment cycle, 210 children were randomized to treatment with aboBoNT-A 2 U/kg, 8 U/kg or …
Switching Adult Patients With Spasticity From Onabotulinumtoxina To Abobotulinumtoxina: A Real-World Data Analysis Across Three Us-Based Treatment Centers, Nate Way, Edward Dabrowski, Mitchell Paulin, Martin Taylor, John Madden, Amandeep Mann, Jonathan Bouchard
Switching Adult Patients With Spasticity From Onabotulinumtoxina To Abobotulinumtoxina: A Real-World Data Analysis Across Three Us-Based Treatment Centers, Nate Way, Edward Dabrowski, Mitchell Paulin, Martin Taylor, John Madden, Amandeep Mann, Jonathan Bouchard
Conference Presentation Abstracts
Introduction: The therapeutic impact of botulinum toxin type A (BoNT-A) as first-line treatment for adult focal spasticity is well established across numerous therapeutic guidelines. However, relatively little real-world evidence exists to inform clinician decision-making when considering switching patients between BoNT-A products. This 5-year retrospective study aims to illustrate the safe transitioning of patients from onabotulinumtoxinA (ONA) to abobotulinumtoxinA (ABO) therapy in US centers that have considerable experience with BoNT-A usage in adults with spasticity.
Methods: Chart data from patients with upper limb spasticity (ULS), lower limb spasticity (LLS), or upper and lower limb spasticity (ULS+LLS) aged >18 years were collected …